title: Pleural resection and pleural infusion chemotherapy for therapy of malignant pleural mesothelioma.
abstract: The aim of this study was to evaluate effective treatment methods of malignant pleural mesothelioma (MPM). Twenty-three patients with MPM were cured by pleural infusion chemotherapy after surgery. Median survival time and the 1-, 2-, and 3-year survival rates were analyzed on the basis of follow-up. Median survival time of all patients was 15 months (range: 3 to 89 months); the 1-, 2-, and 3-year survival rates were 69.6, 43.5, and 13.0%, respectively. The 1-year survival rates of patients in stages I, II, and III were 83.3, 62.5, and 33.3%, respectively, the 2-year survival rates were 50, 37.5, and 33.3%, respectively, and the 3-year survival rates were 34, 23, and 0%, respectively. Surgery-oriented comprehensive treatment was adopted for MPM, which could improve the prognosis and life quality of patients to some extent.
authors.affiliation: Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Pharmacy, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
authors.forename: Q
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
authors.forename: W
authors.initials: W
authors.lastname: Zhao
authors.affiliation: Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
authors.forename: J
authors.initials: J
authors.lastname: Duan
authors.affiliation: Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China jzcn2000@163.com.
authors.forename: T
authors.initials: T
authors.lastname: Huang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007263:Infusions, Parenteral; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy* / Q000601:surgery; D000086002:Mesothelioma, Malignant; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use*; D011184:Postoperative Period
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin; D017239:Paclitaxel